Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "CTO"

4799 News Found

Zydus Wellness net sales up by 113.7% in Q3 FY26
News | February 04, 2026

Zydus Wellness net sales up by 113.7% in Q3 FY26

Glucon-D maintained its leadership position with a 59% MAT market share


Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%
News | February 03, 2026

Artemis Medicare reports strong Q3 growth: revenue up 17%, net profit up 8%

Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh


Lupin & TB Alliance team up to push groundbreaking TB drug forward
News | February 03, 2026

Lupin & TB Alliance team up to push groundbreaking TB drug forward

TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide


Indoco Remedies bags USFDA nod for Lacosamide oral solution
News | February 02, 2026

Indoco Remedies bags USFDA nod for Lacosamide oral solution

The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa


Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
News | February 02, 2026

Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact

The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up


Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
Policy | February 01, 2026

Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare

The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education


Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
News | January 31, 2026

Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY

rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million


Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
News | January 30, 2026

Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%

The base Gland business posted ?11,790 million in revenue, up 16% YoY


Biocon Biologics gets credit boost from S&P, outlook stable
News | January 30, 2026

Biocon Biologics gets credit boost from S&P, outlook stable

The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’